earnings
confidence high
sentiment positive
materiality 0.70
CVRx Q2 revenue $5.0M (+61% YoY); HF revenue up 90% in US; FY guidance raised
CVRx, Inc.
2022-Q2 EPS reported
-$0.49
revenue$9,107,000
- Revenue $5.0M (+61% YoY), US HF revenue $3.8M (+90% YoY) driven by territory expansion.
- Active US implanting centers reached 71 (+27% QoQ); sales territories grew to 20 from 8 a year ago.
- Net loss narrowed to $11.1M ($0.54/shr) from $17.7M; cash $121.3M at quarter end.
- FY2022 revenue guidance raised lower end to $20.5M (range $20.5-$23.0M); gross margin guidance 75-76%.
- Received FDA approval for new tablet programmer and MR conditional labeling for Barostim.